From 1st April 2026, Mogalizumab (brand name POTELIGEO®) will be available on the PBS for adults (>18yrs of age) with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome, who have received at least one prior systemic therapy or treatment.
Mogalizumab (POTELIGEO®) is a monoclonal antibody treatment. It is now available on the Pharmaceutical Benefits Scheme (PBS) in Australia for people with Refractory or Relapsed Cutaneous T-cell Lymphoma who have had one prior systemic therapy. For more information on Poteligeo, you can read the full Product Information (PI) or see how it is administered here: EviQ – Mogamulizumab..
Patients living with CTCL and their families should discuss treatment options with their specialist. Refer to the Consumer Medicine Information or speak to your haematologist for further information.
What are Monoclonal Antibodies?
The word monoclonal means made from one (mono) single type of cell which is then cloned (or duplicated) many times. Scientists make monoclonal antibodies (MABs) in a laboratory, so they are all the same, and target a specific antigen (a protein or receptor) on the lymphoma cells. Monoclonal antibodies help boost your body’s natural ability to fight CTCL.
Mogamulizumab is a humanized monoclonal antibody (MAB) directed against CC chemokine receptor 4 (CCR4), which is frequently expressed on leukemic cells of certain blood cancers including CTCL. For more information on how these work, visit: Bispecific Antibodies & Antibody Conjugates.
